Indication
Anemia in chronic kidney disease
Anemia in chronic kidney disease is a common hematologic complication characterized by a subnormal circulating red blood cell mass and hemoglobin level secondary to progressive renal impairment. Read more about Anemia in chronic kidney disease
26 drugs 18 manufacturers
Drugs that treat it
Common Anemia in chronic kidney disease therapies.
INFED (iron dextran complex)
FERAHEME (ferumoxytol)
PROCRIT (epoetin alfa)
EPOGEN (epoetin alfa)
VENOFER (iron sucrose complex)
ARANESP (darbepoetin alfa in polysorbate 80)
ARANESP (darbepoetin alfa in polysorbate 80)
PROCRIT (epoetin alfa)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnemia in chronic kidney disease is a common hematologic complication characterized by a subnormal circulating red blood cell mass and hemoglobin level secondary to progressive renal impairment.
It primarily affects pediatric and adult patients with moderate-to-severe renal dysfunction, increasing in frequency and severity as renal filtration declines.
Pathophysiologically, the condition is typically a normocytic, normochromic, hypoproliferative anemia driven fundamentally by deficient erythropoietin synthesis from damaged renal peritubular interstitial cells.
It is compounded by systemic inflammation with elevated hepcidin concentrations that produce functional iron restriction, shortened erythrocyte survival, and chronic uremic platelet or blood loss.
- nih.gov
Anemia in chronic kidney disease is a common hematologic complication characterized by a subnormal circulating red blood cell mass and hemoglobin level secondary to progressive renal impairment Pathophysiologically, the condition is typically a normocytic, normochromic, hypoproliferative anemia driven fundamentally by deficient erythropoietin synthesis from damaged renal peritubular interstitial cells
- nih.gov
Anemia in chronic kidney disease is a common hematologic complication characterized by a subnormal circulating red blood cell mass and hemoglobin level secondary to progressive renal impairment It primarily affects pediatric and adult patients with moderate-to-severe renal dysfunction, increasing in frequency and severity as renal filtration declines
- nih.gov
It primarily affects pediatric and adult patients with moderate-to-severe renal dysfunction, increasing in frequency and severity as renal filtration declines
- nih.gov
Pathophysiologically, the condition is typically a normocytic, normochromic, hypoproliferative anemia driven fundamentally by deficient erythropoietin synthesis from damaged renal peritubular interstitial cells It is compounded by systemic inflammation with elevated hepcidin concentrations that produce functional iron restriction, shortened erythrocyte survival, and chronic uremic platelet or blood loss
- nih.gov
It is compounded by systemic inflammation with elevated hepcidin concentrations that produce functional iron restriction, shortened erythrocyte survival, and chronic uremic platelet or blood loss
Personalize your experience
Follow Anemia in chronic kidney disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.